Clinical Trial

Experimental Treatment for Patients with Solid Tumors

Study Description

A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors

To better understand the safety and tolerability of ALKS 4230 in humans

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - ALKS 4230

Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period

Drug - ALKS 4230 + pembrolizumab

IV infusion of ALKS 4230 over 30 minutes given daily for 5 consecutive days followed by an off-treatment period; pembrolizumab administered IV once with ALKS 4230 on the first day of each cycle

Additional Information

Official Study Title

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1

Clinical Trial ID

NCT02799095

ParticipAid ID

xbomYe